Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50124 | 0.85 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1IDO1KDM4ENPC1 | |
| SCHEMBL2679546 | 0.76 | RAB9A (0.48) | ALDH1A1L3MBTL1IDO1KDM4ENPC1 | |
| SCHEMBL6135309 | 0.76 | GPR55 (0.39) | ALDH1A1NPC1HSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL7736978 | 0.76 | — | — | |
| SCHEMBL6348373 | 0.76 | CASP3 (0.35) | — | |
| SCHEMBL4954846 | 0.76 | IDO1 (0.43) | ALDH1A1IDO1KDM4ENPC1GAA | |
| SCHEMBL2200428 | 0.74 | GPR55 (0.38) | ALDH1A1NPC1HSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL27651172 | 0.74 | IDO1 (0.42) | ALDH1A1IDO1KDM4ENPC1GAA | |
| SCHEMBL58582 | 0.74 | RAB9A (0.36) | ALDH1A1NPC1HSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL28691784 | 0.73 | HPGD (0.38) | ALDH1A1IDO1KDM4ENPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071609-A | Quantitative flagellum fluorescent marker and standard items | 马凯特大学 | 2018-12-21 | — | — | CN | disclosed |
| CN-108350466-A | Methods and compositions for determining pH | 芝加哥大学 | 2018-07-31 | — | — | CN | disclosed |
| EP-2707364-B1 | PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF | EGIS GYÓGYSZERGYÁR ZRT (HU) | 2016-08-24 | — | — | EP | disclosed |
| US-9260421-B2 | Pharmaceutical intermediates and process for the preparation thereof | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2016-02-16 | — | — | US | disclosed |
| CN-104394853-A | Use of porous nanostructures in delivery | NVIGEN INC | 2015-03-04 | — | — | CN | disclosed |
| CN-104395471-A | Use of IDED Nanostructures in Nucleic Acid Technology | NVIGEN INC | 2015-03-04 | — | — | CN | disclosed |
| CN-104364188-A | Low density, highly porous nano structure | NVIGEN INC | 2015-02-18 | — | — | CN | disclosed |
| US-20140155614-A1 | PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-06-05 | — | — | US | disclosed |
| EP-2707364-A1 | PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2014-03-19 | — | — | EP | disclosed |
| CN-103619832-A | Preparation method of dabigatran etexilate and intermediate thereof | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG | 2014-03-05 | — | — | CN | disclosed |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2003-09-04 | — | — | US | disclosed |
| WO-2003040112-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| CN-1317003-A | Pyrimidine derivatives having antitumor activity | SHIONOGI & CO (JP) | 2001-10-10 | — | — | CN | disclosed |
| EP-0384310-B1 | Process for the preparation of phenyl oxadiazolyl anilines | BASF AG (DE) | 1994-07-06 | — | — | EP | disclosed |
| US-5104991-A | PREPARATION OF PHENYLOXADIAZOLYLANILINES | BASF AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| EP-0384310-A2 | Process for the preparation of phenyl oxadiazolyl anilines | BASF Aktiengesellschaft (DE) | 1990-08-29 | — | — | EP | disclosed |
| US-4003909-A | [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3976657-A | 3-Hetero-5-substituted aminophenyloxadiazoles | E. R. SQUIBB & SONS, INC. (US) | 1976-08-24 | — | — | US | disclosed |
| US-3976657-A | 3-Hetero-5-substituted aminophenyloxadiazoles | E. R. SQUIBB & SONS, INC. (US) | 1976-08-24 | — | — | US | disclosed |
| US-3923777-A | Azo dye from an ortho-oxydiazolylaniline diazo component | BASF AG | 1975-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155614-A1 | PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | TFPI, VKORC1, VKORC1L1 | ALDH1A1 208/4885L3MBTL1 4852/4885IDO1 1855/4885 |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | HAVCR2, HCCS, PCNA | ALDH1A1 984/4885L3MBTL1 3167/4885IDO1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.